Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 10th, 2023 • Alaunos Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED Exclusive License Agreement (the “Agreement”) is entered into as of April 3, 2023 (the “Effective Date”) replaces in its entirety the Exclusive License Agreement entered into on October 5, 2018 (the “ELA Agreement”) by and between Alaunos Therapeutics (formerly known as ZIOPHARM Oncology, Inc.), a Delaware corporation, with its principal place of business at 8030 El Rio, Houston TX 77054 (“Alaunos”), and Precigen, Inc., a Virginia corporation, with its principal place of business at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Precigen”). Alaunos and Precigen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2023 • Alaunos Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Employment Agreement (this “Agreement”) is made and entered into as of November 29, 2021 (the “Effective Date”), notwithstanding that this Agreement may be executed on a different date, by and between Ziopharm Oncology, Inc. (the “Company”), and Melinda K. Lackey (“Executive”). Each of the Company and Executive are referred to herein individually as a “Party” and collectively as the “Parties.”
SEVERANCE AGREEMENTSeverance Agreement • May 10th, 2023 • Alaunos Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Severance Agreement ("Agreement") is made effective as of July 29, 2019 (the "Effective Date") between Drew Deniger ("Employee") and ZIOPHARM Oncology, Inc., a Delaware corporation (the "Company"). Employee and the Company are hereinafter collectively referred to as the "Parties."
